Jack CR Jr, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62.
Article
PubMed
PubMed Central
Google Scholar
Bateman RJ, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012;367(9):795–804.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ittner LM, Gotz J. Amyloid-beta and tau--a toxic pas de deux in Alzheimer’s disease. Nat Rev Neurosci. 2011;12(2):65–72.
Article
CAS
PubMed
Google Scholar
Ferreira D, et al. Meta-review of CSF core biomarkers in Alzheimer’s disease: the state-of-the-art after the new revised diagnostic criteria. Front Aging Neurosci. 2014;6:47.
PubMed
PubMed Central
Google Scholar
Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer’s disease. Nature. 2009;461(7266):916–22.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhou B, et al. Validity of cerebrospinal fluid biomarkers as endpoints in early-phase clinical trials for Alzheimer's disease. J Alzheimers Dis. 2009;18(1):89–102.
Article
CAS
PubMed
Google Scholar
Jack CR Jr, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 2010;9(1):119–28.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ardura-Fabregat A, et al. Targeting neuroinflammation to treat Alzheimer’s disease. CNS Drugs. 2017;31(12):1057–82.
Article
CAS
PubMed
PubMed Central
Google Scholar
Calsolaro V, Edison P. Neuroinflammation in Alzheimer’s disease: current evidence and future directions. Alzheimers Dement. 2016;12(6):719–32.
Article
PubMed
Google Scholar
Medeiros R, LaFerla FM. Astrocytes: conductors of the Alzheimer disease neuroinflammatory symphony. Exp Neurol. 2013;239:133–8.
Article
CAS
PubMed
Google Scholar
El Khoury JB, et al. CD36 mediates the innate host response to beta-amyloid. J Exp Med. 2003;197(12):1657–66.
Article
PubMed
PubMed Central
CAS
Google Scholar
Steardo L Jr, et al. Does neuroinflammation turn on the flame in Alzheimer’s disease? Focus on astrocytes. Front Neurosci. 2015;9:259.
Article
PubMed
PubMed Central
Google Scholar
Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015;16(6):358–72.
Article
CAS
PubMed
Google Scholar
Carter SF, et al. Astrocyte biomarkers in Alzheimer’s disease. Trends Mol Med. 2019;25(2):77–95.
Article
CAS
PubMed
Google Scholar
Bonneh-Barkay D, et al. Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation. Brain pathology (Zurich). 2012;22(4):530–46.
Article
CAS
Google Scholar
Donato R, et al. S100B's double life: intracellular regulator and extracellular signal. Biochim Biophys Acta. 2009;1793(6):1008–22.
Article
CAS
PubMed
Google Scholar
Yang Z, Wang KK. Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci. 2015;38(6):364–74.
Article
CAS
PubMed
PubMed Central
Google Scholar
Rehli M, et al. Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J Biol Chem. 2003;278(45):44058–67.
Article
CAS
PubMed
Google Scholar
Craig-Schapiro R, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer’s disease. Biol Psychiatry. 2010;68(10):903–12.
Article
CAS
PubMed
PubMed Central
Google Scholar
Querol-Vilaseca M, et al. YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer’s disease and other tauopathies. J Neuroinflammation. 2017;14(1):118.
Article
PubMed
PubMed Central
CAS
Google Scholar
Griffin WS, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A. 1989;86(19):7611–5.
Article
CAS
PubMed
PubMed Central
Google Scholar
Mrak RE, Sheng JG, Griffin WS. Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer’s disease. J Neuropathol Exp Neurol. 1996;55(3):273–9.
Article
CAS
PubMed
Google Scholar
Hanzel DK, et al. High-throughput quantitative histological analysis of Alzheimer’s disease pathology using a confocal digital microscanner. Nat Biotechnol. 1999;17(1):53–7.
Article
CAS
PubMed
Google Scholar
Muramori F, Kobayashi K, Nakamura I. A quantitative study of neurofibrillary tangles, senile plaques and astrocytes in the hippocampal subdivisions and entorhinal cortex in Alzheimer’s disease, normal controls and non-Alzheimer neuropsychiatric diseases. Psychiatry Clin Neurosci. 1998;52(6):593–9.
Article
CAS
PubMed
Google Scholar
Vehmas AK, et al. Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease. Neurobiol Aging. 2003;24(2):321–31.
Article
PubMed
Google Scholar
Olsson B, et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673–84.
Article
CAS
PubMed
Google Scholar
Alcolea D, et al. Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer’s disease. Neurobiol Aging. 2015;36(6):2018–23.
Article
CAS
PubMed
Google Scholar
Alcolea D, et al. Relationship between beta-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer’s disease. J Alzheimers Dis. 2014;42(1):157–67.
Article
CAS
PubMed
Google Scholar
Antonell A, et al. Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer’s disease. J Alzheimers Dis. 2014;42(3):901–8.
Article
CAS
PubMed
Google Scholar
Melah KE, et al. Cerebrospinal fluid markers of Alzheimer’s disease pathology and microglial activation are associated with altered white matter microstructure in asymptomatic adults at risk for Alzheimer’s disease. J Alzheimers Dis. 2016;50(3):873–86.
Article
CAS
PubMed
PubMed Central
Google Scholar
Olsson B, et al. Association of cerebrospinal fluid neurofilament light protein levels with cognition in patients with dementia, motor neuron disease, and movement disorders. JAMA Neurol. 2019;76(3):318–25.
Article
PubMed
Google Scholar
Hov KR, et al. Cerebrospinal fluid S100B and Alzheimer’s disease biomarkers in hip fracture patients with delirium. Dement Geriatr Cogn Dis Extra. 2017;7(3):374–85.
Article
PubMed
PubMed Central
Google Scholar
Ishiki A, et al. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer’s disease, dementia with Lewy bodies, and frontotemporal lobar degeneration. J Neurochem. 2016;136(2):258–61.
Article
CAS
PubMed
Google Scholar
Small SA, et al. A pathophysiological framework of hippocampal dysfunction in ageing and disease. Nat Rev Neurosci. 2011;12(10):585–601.
Article
CAS
PubMed
PubMed Central
Google Scholar
Snowden JS, et al. Cognitive phenotypes in Alzheimer’s disease and genetic risk. Cortex. 2007;43(7):835–45.
Article
PubMed
Google Scholar
Dubois B, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614–29.
Article
PubMed
Google Scholar
Jorm AF. A short form of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): development and cross-validation. Psychol Med. 1994;24(1):145–53.
Article
CAS
PubMed
Google Scholar
McKhann GM, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement. 2011;7(3):263–9.
Article
Google Scholar
McKeith IG, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology. 2017;89(1):88–100.
Article
PubMed
PubMed Central
Google Scholar
Winblad B, et al. Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256(3):240–6.
Article
CAS
PubMed
Google Scholar
Duits FH, et al. The cerebrospinal fluid “Alzheimer profile”: easily said, but what does it mean? Alzheimers Dement. 2014;10(6):713–723.e2.
Article
PubMed
Google Scholar
Lezak MD. Neuropsychological assessment. Oxford: Oxford University Press; 2012.
Google Scholar
Wechsler D. WMS-R : Wechsler Memory Scale-Revised : manual. San Antonio: Harcourt Brace Jovanovich; 1987.
Google Scholar
Shao Z, et al. What do verbal fluency tasks measure? Predictors of verbal fluency performance in older adults. Front Psychol. 2014;5:772.
Article
PubMed
PubMed Central
Google Scholar
Tombaugh TN. Trail Making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol. 2004;19(2):203–14.
Article
PubMed
Google Scholar
Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;18(6):643–62.
Article
Google Scholar
Wechsler D. Wechsler adult intelligence scale–Fourth Edition (WAIS–IV), vol. 22. San Antonio: NCS Pearson; 2008. p. 498.
Google Scholar
DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837–45.
Article
CAS
PubMed
Google Scholar
Tibshirani R. Regression shrinkage and selection via the lasso. J Royal Stat Soc Series B (Methodological). 1996;58(1):267–88.
Article
Google Scholar
Hofner B, Boccuto L, Göker M. Controlling false discoveries in high-dimensional situations: boosting with stability selection. BMC Bioinformatics. 2015;16(1):144.
Article
PubMed
PubMed Central
Google Scholar
Meinshausen N, Bühlmann P. Stability selection. J Royal Stat Soc: Series B (Statistical Methodology). 2010;72(4):417–73.
Article
Google Scholar
Consensus report of the Working Group on: Molecular and biochemical markers of Alzheimer’s disease. The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. Neurobiol Aging, 1998. 19(2): p. 109–116.
Ganguli M, et al. Age and education effects and norms on a cognitive test battery from a population-based cohort: the Monongahela-Youghiogheny Healthy Aging Team. Aging Ment Health. 2010;14(1):100–7.
Article
PubMed
PubMed Central
Google Scholar
Alcolea D, et al. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. Neurology. 2015;85(7):626–33.
Article
CAS
PubMed
Google Scholar
Mattsson N, et al. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer’s disease. EMBO Mol Med. 2016;8(10):1184–96.
Article
CAS
PubMed
PubMed Central
Google Scholar
Olsson, B., et al., Association of cerebrospinal fluid neurofilament light protein levels with cognition in patients with dementia, motor neuron disease, and movement disorders. JAMA Neurol. 2019;76(3):318–25.
Gangishetti U, et al. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease. Alzheimers Res Ther. 2018;10(1):98.
Article
PubMed
PubMed Central
CAS
Google Scholar
Kester MI, et al. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer’s disease in a memory clinic cohort. Alzheimers Res Ther. 2015;7(1):59.
Article
PubMed
PubMed Central
CAS
Google Scholar
Weissberger GH, et al. Diagnostic accuracy of memory measures in Alzheimer’s dementia and mild cognitive impairment: a systematic review and meta-analysis. Neuropsychol Rev. 2017;27(4):354–88.
Article
PubMed
PubMed Central
Google Scholar
Zetterberg H, et al. Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA neurology. 2016;73(1):60–7.
Article
PubMed
PubMed Central
Google Scholar
Guhra M, et al. Linking CSF and cognition in Alzheimer’s disease: reanalysis of clinical data. Exp Gerontol. 2016;73:107–13.
Article
CAS
PubMed
Google Scholar
Nordlund A, et al. Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI. J Int Neuropsychol Soc. 2008;14(4):582–90.
Article
PubMed
Google Scholar
Rolstad S, et al. Amyloid-beta(4)(2) is associated with cognitive impairment in healthy elderly and subjective cognitive impairment. J Alzheimers Dis. 2011;26(1):135–42.
Article
CAS
PubMed
Google Scholar
Bendlin BB, et al. CSF T-Tau/Abeta42 predicts white matter microstructure in healthy adults at risk for Alzheimer's disease. PLoS One. 2012;7(6):e37720.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bertens D, et al. Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer’s disease. Alzheimers Dement. 2015;11(5):511–22.
Article
PubMed
Google Scholar
Darreh-Shori T, et al. Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer’s disease. Neurobiol Aging. 2013;34(11):2465–81.
Article
CAS
PubMed
Google Scholar
Sala-Llonch R, et al. Inflammation, amyloid, and atrophy in the aging brain: relationships with longitudinal changes in cognition. J Alzheimers Dis. 2017;58(3):829–40.
Article
CAS
PubMed
Google Scholar
Bos I, et al. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer’s disease spectrum. Alzheimers Dement. 2019;15(5):644–54.
Article
PubMed
Google Scholar
Sutphen CL, et al. Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age. JAMA Neurol. 2015;72(9):1029–42.
Article
PubMed
PubMed Central
Google Scholar